Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effects of 18 weeks of high-dose
vitamin D3 supplementation compared with standard-dose vitamin D3 supplementation on immune
function, glucose homeostasis, and bone metabolism in children with systemic lupus
erythematosus (SLE) and serum 25-hydroxyvitamin D [25(OH)D] levels ≤20 ng/mL.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Autoimmunity Centers of Excellence
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins